Premium
Anti‐dyskinetic mechanisms of amantadine and dextromethorphan in the 6‐OHDA rat model of Parkinson’s disease: role of NMDA vs. 5‐HT1A receptors
Author(s) -
Paquette Melanie A.,
Martinez Alex A.,
Macheda Teresa,
Meshul Charles K.,
Johnson Steven W.,
Berger S. Paul,
Giuffrida Andrea
Publication year - 2012
Publication title -
european journal of neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.346
H-Index - 206
eISSN - 1460-9568
pISSN - 0953-816X
DOI - 10.1111/j.1460-9568.2012.08243.x
Subject(s) - amantadine , dextromethorphan , neuroscience , parkinson's disease , memantine , nmda receptor , pharmacology , medicine , receptor , disease , psychology
Amantadine and dextromethorphan suppress levodopa (L‐DOPA)‐induced dyskinesia (LID) in patients with Parkinson’s disease (PD) and abnormal involuntary movements (AIMs) in the unilateral 6‐hydroxydopamine (6‐OHDA) rat model. These effects have been attributed to N ‐methyl‐ d ‐aspartate (NMDA) antagonism. However, amantadine and dextromethorphan are also thought to block serotonin (5‐HT) uptake and cause 5‐HT overflow, leading to stimulation of 5‐HT 1A receptors, which has been shown to reduce LID. We undertook a study in 6‐OHDA rats to determine whether the anti‐dyskinetic effects of these two compounds are mediated by NMDA antagonism and/or 5‐HT 1A agonism. In addition, we assessed the sensorimotor effects of these drugs using the Vibrissae‐Stimulated Forelimb Placement and Cylinder tests. Our data show that the AIM‐suppressing effect of amantadine was not affected by the 5‐HT 1A antagonist WAY‐100635, but was partially reversed by the NMDA agonist d ‐cycloserine. Conversely, the AIM‐suppressing effect of dextromethorphan was prevented by WAY‐100635 but not by d ‐cycloserine. Neither amantadine nor dextromethorphan affected the therapeutic effects of L‐DOPA in sensorimotor tests. We conclude that the anti‐dyskinetic effect of amantadine is partially dependent on NMDA antagonism, while dextromethorphan suppresses AIMs via indirect 5‐HT 1A agonism. Combined with previous work from our group, our results support the investigation of 5‐HT 1A agonists as pharmacotherapies for LID in PD patients.